BioCentury | Dec 19, 2019

Combined inhibition of EIF4A1 and glutaminase for pancreatic cancer

...cell lines. Treatment with a GLS inhibitor tool compound or CB-839, a GLS inhibitor from Calithera Biosciences Inc....
BioCentury | Jul 13, 2019
Finance

How crossover, insider support and big money correlated with performance across 1H19 IPOs

...NASDAQ:GNCA) 6/19/19 $36.8 $85.9 $96.2 12% Rockwell Medical Inc. (NASDAQ:RMTI) 6/18/19 $18.8 $190.2 $190.8 0% Calithera Biosciences Inc....
BioCentury | Jun 19, 2019
Financial News

June 19 Financial Quick Takes: Stoke rises after IPO; plus Polaris, Woodford, follow-ons

...to a survival benefit in the Phase II ENTRATA study to treat renal cell carcinoma, Calithera Biosciences Inc....
...SVB Leerink, Wells Fargo and William Blair are underwriters. Paul Bonanos, Associate Editor Biohaven Pharmaceutical Holding Co. Ltd. Calithera Biosciences Inc. Kura...
BioCentury | Jun 18, 2019
Clinical News

June 17 Clinical Quick Takes: VBI's HBV vaccine misses secondary endpoint, plus ArQule, Verastem and more

...following the first cycle of treatment. Calithera’s telaglenastat improves PFS in Phase II for RCC Calithera Biosciences Inc....
...and Hongjiang Li, Staff Writers Copiktra, duvelisib (IPI-145, ink-1197) Miransertib (ARQ 092) Sci-B-Vac (Brand), Sci-B-Vac (Other) Amgen Inc. ArQule Inc. BioNTech SE Calithera Biosciences Inc. VBI...
BioCentury | Apr 10, 2019
Distillery Therapeutics

Diazooxohexanoate-based prodrug of a GLS inhibitor for lymphoma

...5 μM, respectively). Next steps could include testing the prodrug in mouse models of lymphoma. Calithera Biosciences Inc....
BioCentury | Mar 8, 2019
Company News

TNBC gets its first targeted agent with Tecentriq approval

...began to show promise in the clinic in 2016, Susan Molineaux, president and CEO of Calithera Biosciences Inc....
BioCentury | Dec 19, 2018
Distillery Therapeutics

Cancer

...Phase II testing for acute myelogenous leukemia (AML) and Phase I/II testing for liver cancer. Calithera Biosciences Inc....
BioCentury | Nov 15, 2018
Product R&D

Tempest takes PPAR alpha into cancer

...feeds an energy pathway in tumor cells and exerts an immunosuppressive effect on immune cells. Calithera Biosciences Inc.’s...
...data emerging from the clinic.” Companies and Institutions Mentioned 3-V Biosciences Inc., Menlo Park, Calif. Calithera Biosciences Inc....
BioCentury | Sep 28, 2018
Targets & Mechanisms

Cell metabolism’s migration

...two companies have compounds targeting the glutamine pathway: the small molecule GLS inhibitor CB-839 from Calithera Biosciences Inc....
...that will first make the cells more similar to one another.” Companies and Institutions Mentioned Calithera Biosciences Inc....
BioCentury | Sep 20, 2018
Distillery Therapeutics

Cancer

...alone. Next steps could include testing CB-839 plus radiation in other models of IDH1-mutant glioma. Calithera Biosciences Inc....
Items per page:
1 - 10 of 62
BioCentury | Dec 19, 2019

Combined inhibition of EIF4A1 and glutaminase for pancreatic cancer

...cell lines. Treatment with a GLS inhibitor tool compound or CB-839, a GLS inhibitor from Calithera Biosciences Inc....
BioCentury | Jul 13, 2019
Finance

How crossover, insider support and big money correlated with performance across 1H19 IPOs

...NASDAQ:GNCA) 6/19/19 $36.8 $85.9 $96.2 12% Rockwell Medical Inc. (NASDAQ:RMTI) 6/18/19 $18.8 $190.2 $190.8 0% Calithera Biosciences Inc....
BioCentury | Jun 19, 2019
Financial News

June 19 Financial Quick Takes: Stoke rises after IPO; plus Polaris, Woodford, follow-ons

...to a survival benefit in the Phase II ENTRATA study to treat renal cell carcinoma, Calithera Biosciences Inc....
...SVB Leerink, Wells Fargo and William Blair are underwriters. Paul Bonanos, Associate Editor Biohaven Pharmaceutical Holding Co. Ltd. Calithera Biosciences Inc. Kura...
BioCentury | Jun 18, 2019
Clinical News

June 17 Clinical Quick Takes: VBI's HBV vaccine misses secondary endpoint, plus ArQule, Verastem and more

...following the first cycle of treatment. Calithera’s telaglenastat improves PFS in Phase II for RCC Calithera Biosciences Inc....
...and Hongjiang Li, Staff Writers Copiktra, duvelisib (IPI-145, ink-1197) Miransertib (ARQ 092) Sci-B-Vac (Brand), Sci-B-Vac (Other) Amgen Inc. ArQule Inc. BioNTech SE Calithera Biosciences Inc. VBI...
BioCentury | Apr 10, 2019
Distillery Therapeutics

Diazooxohexanoate-based prodrug of a GLS inhibitor for lymphoma

...5 μM, respectively). Next steps could include testing the prodrug in mouse models of lymphoma. Calithera Biosciences Inc....
BioCentury | Mar 8, 2019
Company News

TNBC gets its first targeted agent with Tecentriq approval

...began to show promise in the clinic in 2016, Susan Molineaux, president and CEO of Calithera Biosciences Inc....
BioCentury | Dec 19, 2018
Distillery Therapeutics

Cancer

...Phase II testing for acute myelogenous leukemia (AML) and Phase I/II testing for liver cancer. Calithera Biosciences Inc....
BioCentury | Nov 15, 2018
Product R&D

Tempest takes PPAR alpha into cancer

...feeds an energy pathway in tumor cells and exerts an immunosuppressive effect on immune cells. Calithera Biosciences Inc.’s...
...data emerging from the clinic.” Companies and Institutions Mentioned 3-V Biosciences Inc., Menlo Park, Calif. Calithera Biosciences Inc....
BioCentury | Sep 28, 2018
Targets & Mechanisms

Cell metabolism’s migration

...two companies have compounds targeting the glutamine pathway: the small molecule GLS inhibitor CB-839 from Calithera Biosciences Inc....
...that will first make the cells more similar to one another.” Companies and Institutions Mentioned Calithera Biosciences Inc....
BioCentury | Sep 20, 2018
Distillery Therapeutics

Cancer

...alone. Next steps could include testing CB-839 plus radiation in other models of IDH1-mutant glioma. Calithera Biosciences Inc....
Items per page:
1 - 10 of 62